Takeda said more than half of plaque psoriasis patients treated with zasocitinib achieved clear or almost clear skin in two Phase 3 studies. Regulatory submissions for the TYK2 inhibitor are planned for 2026 and clinical trials are ongoing in other indications.
The post Takeda Drug From $4B Deal Succeeds in Two Pivotal Plaque Psoriasis Trials appeared first on MedCity News.
